Hot Flashes in Prostate Cancer Market Expected to Strengthen Through 2032 with Growing Awareness and Novel Interventions
The hot flashes in prostate cancer market is poised for significant growth through 2032, driven by increasing awareness, improved diagnosis, and the development of more effective interventions from companies such as, Foundation Medicine, Bayer, Ipsen, Exelixis, AstraZeneca, and Synact Pharma, among others, addressing this debilitating side effect of androgen deprivation therapy (ADT).
DelveInsight's " Hot Flashes in Prostate Cancer Market Insights, Epidemiology and Market Forecast-2032" report provides an in-depth understanding of hot flashes in prostate cancer patients, historical and forecasted epidemiology trends, as well as market dynamics across the 7MM, which include, the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The report covers current treatment practices, emerging therapies, market share of individual treatments, and hot flashes in the prostate cancer market size, offering valuable insights for healthcare stakeholders and pharmaceutical developers.
The US currently represents the largest share of the hot flashes in the prostate cancer market, with substantial growth projected through 2032. This growth trajectory is supported by favorable reimbursement policies, increased awareness among healthcare providers, and the rapid adoption of novel interventions targeting this specific symptom. The EU4 countries and the United Kingdom collectively constitute the second-largest market segment, while Japan shows promising growth potential as awareness of this condition increases in the Asia-Pacific region.
Download the Hot Flashes in Prostate Cancer Market Forecast Report to understand which factors are driving the Hot Flashes in Prostate Cancer market @ Hot Flashes in Prostate Cancer Market Trends.
Hot flashes, commonly associated with menopause in women, have emerged as a significant phenomenon in men undergoing prostate cancer treatment, particularly those receiving androgen deprivation therapy. ADT works by reducing testosterone levels, which often triggers sudden and intense waves of heat accompanied by perspiration and flushed skin. This treatment-induced side effect affects a substantial proportion of prostate cancer patients, with the prevalence expected to increase as ADT remains a cornerstone therapy for hormone-sensitive prostate cancer management. Traditionally seen as a female experience, these vasomotor symptoms now represent a significant unmet need in male oncology care, affecting treatment adherence and quality of life.
DelveInsight's analysis shows that between 30% and 80% of men with prostate cancer, especially those undergoing androgen deprivation therapy (ADT), experience hot flashes. The onset of hot flashes typically occurs within weeks of starting hormone therapy, and the symptoms can persist for months or even years. Furthermore, the prevalence is higher in older men, with a mean age of onset around 70, and the median number of hot flashes reported is about three per day. While most men eventually experience remission of symptoms, a significant proportion continue to have hot flashes long-term, which can negatively affect quality of life.
Discover evolving trends in the Hot Flashes in Prostate Cancer patient pool forecasts @ Hot Flashes in Prostate Cancer Epidemiological Analysis.
The current landscape of hot flash management in prostate cancer encompasses various approaches, including pharmacological interventions such as hormone replacement therapies, antidepressants, anticonvulsants, and non-pharmacological strategies, including lifestyle modifications and wearable cooling technologies. The market has witnessed an increased focus on addressing this side effect, prompting innovative research into targeted therapies that specifically address the neurohormonal pathways involved in hot flash generation without compromising the efficacy of anticancer treatments. This represents a significant shift from historical approaches that often considered hot flashes an inevitable and acceptable consequence of life-extending prostate cancer therapies.
Recent developments have significantly shaped the evolving landscape of hot flashes management in prostate cancer. Several effective treatments, such as Oxybutynin, an oral medication traditionally used for overactive bladder, have shown strong results in reducing both the frequency and severity of hot flashes in men on ADT, as demonstrated in a 2024 phase II trial.
Non-hormonal agents like venlafaxine have also shown efficacy in smaller studies. New hormone therapies, such as ORGOVYX (relugolix), the first oral GnRH antagonist approved by the FDA, offer convenient alternatives to injectable treatments and may help manage hot flashes as part of overall ADT regimens. Additionally, a ready-to-use 3-month leuprolide depot formulation is nearing FDA approval, promising more flexible treatment options for advanced prostate cancer. Research is ongoing into novel agents targeting the neurokinin pathway, such as fezolinetant and elinzanetant, which have shown promise in reducing hot flashes in cancer patients, although data in prostate cancer specifically are still emerging.
Discover evolving trends in the Hot Flashes in Prostate Cancer treatment landscape @ Hot Flashes in Prostate Cancer Recent Developments.
Looking ahead, the hot flashes in prostate cancer market is expected to witness substantial growth driven by several factors, including the rising incidence of prostate cancer, increased adoption of ADT as a standard treatment approach, growing awareness among healthcare providers about the impact of hot flashes on treatment adherence and patient quality of life, and the development of novel targeted interventions. Companies such as Foundation Medicine, Bayer (ETR: BAYN), Ipsen (EPA: IPN), Exelixis (NASDAQ: EXEL), AstraZeneca (NASDAQ: AZN), and Synact Pharma (STO: SYNACT), among others, are actively involved in this space, reflecting a growing focus on both cancer control and symptom management.
Additionally, the integration of digital health solutions and wearable technologies for symptom monitoring and management presents exciting opportunities for market expansion. However, challenges remain, including the need for standardized assessment tools for hot flash severity in men, limited awareness among some healthcare providers, and reimbursement barriers for symptom-focused treatments.
DelveInsight's analysis emphasizes that companies developing therapies for hot flashes in prostate cancer patients should focus on interventions that not only reduce symptom frequency and severity but also maintain the therapeutic efficacy of anticancer treatments. The increasing recognition of hot flashes as a legitimate treatment target rather than merely an acceptable side effect represents a paradigm shift in prostate cancer management, opening new avenues for therapeutic development and market growth.
Table of Contents
1. Key Insights
2. Executive Summary of Hot Flashes in Prostate Cancer
3. Hot Flashes in Prostate Cancer Competitive Intelligence
4. Hot Flashes in Prostate Cancer: Market Overview at a Glance
5. Hot Flashes in Prostate Cancer: Disease Background and Overview
6. Patient Journey
7. Hot Flashes in Prostate Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Hot Flashes in Prostate Cancer Unmet Needs
10. Key Endpoints of Hot Flashes in Prostate Cancer Treatment
11. Hot Flashes in Prostate Cancer Marketed Products
12. Hot Flashes in Prostate Cancer Emerging Therapies
13. Hot Flashes in Prostate Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Hot Flashes in Prostate Cancer
17. KOL Views
18. Hot Flashes in Prostate Cancer Market Drivers
19. Hot Flashes in Prostate Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
14 hours ago
- National Post
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
Article content GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood within just 35 minutes. Article content sTREM2 is a promising biomarker of microglial activation, offering researchers insights into neuroinflammation linked to Alzheimer's and other neurodegenerative diseases. sTREM2 can be valuable for capturing the dynamics of inflammatory responses or for monitoring inflammatory modulators. This test complements Fujirebio's growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company's leading position in advancing neuro biomarker research tools and diagnostics. Article content Article content 'By adding sTREM2 to our neuro portfolio, we're enabling a more comprehensive view of neurological disease mechanisms,' Article content said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. 'sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation – offering a more complete picture of the disease on a single platform.' Article content The new test allows researchers and clinical research professionals to further study and understand the potential clinical utility of this promising microglial biomarker. The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements. Article content About Fujirebio Article content Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Article content Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. Article content Article content Article content Email: Article content pr@ Article content For investors and analysts: Article content Article content IR/SR Dept. Article content Article content Article content
CTV News
18 hours ago
- CTV News
UN Security Council to vote on Gaza ceasefire resolution amid humanitarian crisis
UNITED NATIONS — The U.N. Security Council scheduled a vote Wednesday on a resolution which demands 'an immediate, unconditional and permanent ceasefire in Gaza respected by all parties.' U.N. diplomats said the United States is likely to veto it. The resolution, drafted by the council's 10 elected members who serve two-year terms, reiterates its demand for the release of all hostages held by Hamas and other groups following their Oct. 7, 2023 surprise attack in southern Israel. Calling the humanitarian situation in Gaza 'catastrophic,' the proposed resolution also demands 'the immediate and unconditional lifting of all restrictions on the entry of humanitarian aid into Gaza and its safe and unhindered distribution at scale, including by the U.N. and humanitarian partners.' The vote, scheduled for late Wednesday afternoon, comes amid near-daily shootings following the establishment by an Israeli and U.S.-backed foundation of aid distribution points inside Israeli military zones, a system it says is designed to circumvent Hamas. The United Nations has rejected the new system, saying it doesn't address Gaza's mounting hunger crisis, allows Israel to use aid as a weapon, and doesn't comply with the humanitarian principles of neutrality, impartiality and independence. The draft resolution demands the restoration of all essential humanitarian services in line with those principles, international humanitarian law and U.N. Security Council resolutions. Several U.N. diplomats from different countries, speaking on condition of anonymity Tuesday because discussions have been private, said they expect the United States to veto the resolution. The U.S. Mission to the United Nations said it had no comment on the draft resolution at this time. Israel's U.N. Mission did not respond to a request for comment on the draft. Gaza's roughly 2 million people are almost completely reliant on international aid because Israel's offensive has destroyed nearly all of Gaza's food production capabilities. Israel imposed a blockade on supplies into Gaza on March 2, and limited aid began to enter again late last month after pressure from allies and warnings of famine. U.N. spokesman Stephane Dujarric said Tuesday that the needs in Gaza are enormous and what's getting into Gaza from the U.N. 'is still just a trickle.' Since the complete blockade was partly lifted, he said, just over 620 truckloads have made it from Israel to the Palestinian side of the Kerem Shalom crossing, and only about 370 truckloads – mainly with flour, food and medical and nutrition items __ have gotten closer to people in need, with some looted including by armed gangs. 'The unimpeded entry of humanitarian assistance at scale must be restored immediately,' Dujarric said. 'The U.N. must be allowed to work in safety and in security under conditions of full respect for humanitarian principles.' Since Oct. 7, 2023, the Security Council has voted on 14 Gaza-related resolutions and approved four. The last resolution was also proposed by the 10 elected council members and also demanded 'an immediate, unconditional and permanent cease-fire to be respected by all parties.' Fourteen of the 15 council members voted in favor last Nov. 20, but the U.S. vetoed the resolution because it was not linked to the immediate and unconditional release of all hostages. Hamas-led militants killed around 1,200 people, mostly civilians, and took 251 people hostage in the Oct. 7, 2023, attack into southern Israel that ignited the war. They are still holding 58 hostages, a third of them believed to be alive, after most of the rest were released in ceasefire agreements or other deals. Israel's military campaign has killed more than 54,000 Palestinians, mostly women and children, according to Gaza's Health Ministry, which doesn't say how many of the dead were civilians or combatants. The ministry is led by medical professionals but reports to the Hamas-run government. Its toll is seen as generally reliable by U.N. agencies and independent experts, though Israel has challenged its numbers. Edith M. Lederer, The Associated Press
Vancouver Sun
a day ago
- Vancouver Sun
Cowan: Future is hazy for Canadiens centre Kirby Dach
Kent Hughes knew the Canadiens had a lack of depth at the centre position when he took over as GM three years ago. That's why at his first NHL Entry Draft as GM in 2022, Hughes traded a first-round pick and a third-round pick to the Chicago Blackhawks in exchange for Kirby Dach. 'We were looking to improve, get a little bigger, faster in the middle of the ice if we could,' Hughes said after making the trade. 'There's also, in a perfect world, an age component to it so that (Dach) can grow with our young core, and certainly he fit that description for us. We knew he was available potentially, so we spent a good amount of time trying to understand who Kirby Dach was. He went third pick overall (at the 2019 NHL Draft). What's happened with Kirby Dach? Why is Chicago willing to move him? 'I've said it all along, we're going to invest money in developing hockey players and trying to get the most out of their potential, and we believe Kirby has significant potential,' Hughes added. 'We think with the Montreal Canadiens, in this environment, can bring him along and get him to a point where he can be a pretty special centreman.' Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Three years later, there are more questions than answers when it comes to the 24-year-old Dach. As a result, Hughes will head into this off-season once again looking for a second-line centre who can play behind captain Nick Suzuki, either through free agency or a trade. Dach had 10-12-22 totals and was a team-worst minus-29 before suffering a season-ending injury to his right knee that required surgery for the second straight year. He won only 40.3 per cent of his faceoffs. The top centres eligible to become free agents on July 1 are Florida's Sam Bennett, 29, Toronto's John Tavares , 34, Colorado's Brock Nelson , 33, and Dallas's Matt Duchene , 34. Their salary demands will probably be too high for the Canadiens, even if those players had any interest in coming to Montreal. A trade for a younger centreman with NHL experience seems a more likely scenario. Jeff Gorton, the Canadiens' executive vice-president of hockey operations, didn't rule out the possibility of making offer sheets to restricted free agents during a season-ending news conference last month and added he and Hughes weren't limited to looking only at centres to improve their top-six forward situation, which is a priority. The Canadiens had interest in right-winger Jonathan Marchessault as a free agent last summer, but weren't willing to offer the 34-year-old more than a three-year contract. Instead, Marchessault signed a five-year, US$27.5-million deal with Nashville that has an annual salary-cap hit of US$5.5 million and then the 5-foot-9, 185-pounder posted 21-35-56 totals with the Predators. Frank Seravalli of Daily Faceoff reported last week that Marchessault is open to being traded after the Predators finished 30th in the overall NHL standings, with Montreal a favourable landing spot. But the length of Marchessault's contract must still be a concern for Hughes. Dach is heading into the final season of his contract with a US$3.36 million salary-cap hit. 'I still believe in Kirby,' Hughes said at the season-ending news conference with Gorton. 'He has so much potential as a player.' Hughes wouldn't say this is Dach's last chance with the Canadiens, but added it's a very important season for the centre and that he and the team know that. Hughes spoke with Dach during his exit meeting about the importance of him doing everything possible this summer so he can show up at training camp in the best state possible, physically and mentally. Hughes noted that constant negative comments in a hockey market like Montreal can be like 'an avalanche' for a young player who is struggling on the ice. Hughes also said the fact Dach was coming back from a serious knee injury — torn ACL and MCL ligaments in his right knee that limited him to two games in 2023-24 — can't be overlooked and pointed out that while Dach was minus-29 last season, he was minus-2 when he played 58 games during his first season with the Canadiens in 2022-23, posting 14-24-38 totals. 'Obviously, he's had two really tough years and two tough injuries here,' Gorton said about Dach. 'We're going to have to see how he responds this summer to the rehab and going through this again. But there's certainly a place for him in our lineup. It's going to be up to him where that's going to be. He has size, he's competitive, he's got skill, he's a very talented player. I think a lot is in the balance of how his summer goes, with how the rehab's going to go. We saw last year, last season, a slow start coming back from that (injury) particularly in his skating, and he'd be the first to tell you that. 'I think a lot, unfortunately, is going to be what kind of summer he has and what kind of start he has to camp,' Gorton added. 'He's going to need a big camp to get himself going and get started early.'
